Apotex Patent-Cliff Exposure & CMS Drug Spending Portfolio
Apotex (Weston, FL): 20 reconciled FDA prescription therapies (0.3% 2025 to 2030 cliff risk), $289.1M 2024 CMS Part D & Medicaid spend, and 39 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Weston, FL |
| Reconciled FDA Portfolio Therapies | 20 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.3% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $289.1M |
| 2024 Medicare Part D Spend | $177.9M |
| 2024 Medicaid Spend | $111.2M |
| California HCAI SB 17 Filings | 39 WAC filings (max 59.9% 2-yr change) |